CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway

被引:325
作者
Liang, Zhongxing
Brooks, Joann
Willard, Margaret
Liang, Ke
Yoon, Younghyoun
Kang, Seunghee
Shim, Hyunsuk
机构
[1] Winship Canc Ctr, Dept Hematol Oncol, Atlanta, GA 30322 USA
[2] Emory Univ, Dept Radiol, Atlanta, GA 30322 USA
关键词
CXCR4; VEGF; CXCL12; Akt;
D O I
10.1016/j.bbrc.2007.05.182
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
CXC chemokine receptor 4 (CXCR4) has been shown to play a critical role in chemotaxis and homing, which are key steps in cancer metastasis. There is also increasing evidence that links this receptor to angiogenesis; however, its molecular basis remains elusive. Vascular endothelial growth factor (VEGF), one of the major angiogenic factors, promotes the formation of leaky tumor vasculatures that are the hallmarks of tumor progression. Here, we investigated whether CXCR4 induces the expression of VEGF through the PI3K/Akt pathway. Our results showed that CXCR4/CXCL12 induced Akt phosphorylation, which resulted in upregulation of VEGF at both the mRNA and protein levels. Conversely, blocking the activation of Akt signaling led to a decrease in VEGF protein levels; blocking CXCR4/CXCL12 interaction with a CXCR4 antagonist suppressed tumor angiogenesis and growth in vivo. Furthermore, VEGF mRNA levels correlated well with CXCR4 mRNA levels in patient tumor samples. In summary, our study demonstrates that the CXCR4/CXCL12 signaling axis can induce angiogenesis and progression of tumors by increasing expression of VEGF through the activation of PI3K/Akt pathway. Our findings suggest that targeting CXCR4 could provide a potential new anti-angiogenic therapy to suppress the formation of both primary and metastatic tumors. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:716 / 722
页数:7
相关论文
共 27 条
[1]   Akt and hypoxia-inducible factor-1 independently enhance tumor growth and angiogenesis [J].
Arsham, AM ;
Plas, DR ;
Thompson, CB ;
Simon, MC .
CANCER RESEARCH, 2004, 64 (10) :3500-3507
[2]   Tumorigenesis and the angiogenic switch [J].
Bergers, G ;
Benjamin, LE .
NATURE REVIEWS CANCER, 2003, 3 (06) :401-410
[3]   Building better vasculature [J].
Bruick, RK ;
McKnight, SL .
GENES & DEVELOPMENT, 2001, 15 (19) :2497-2502
[4]   Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck [J].
Chen, ZG ;
Zhang, X ;
Li, MF ;
Wang, ZQ ;
Wieand, HS ;
Grandis, JR ;
Shin, DM .
CLINICAL CANCER RESEARCH, 2004, 10 (17) :5930-5939
[5]   Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis [J].
Darash-Yahana, M ;
Pikarsky, E ;
Abramovitch, R ;
Zeira, E ;
Pal, B ;
Karplus, R ;
Beider, K ;
Avniel, S ;
Kasem, S ;
Galun, E ;
Peled, A .
FASEB JOURNAL, 2004, 18 (09) :1240-+
[6]   EPIDERMAL GROWTH-FACTOR RECEPTOR GENE-EXPRESSION IN ESTROGEN RECEPTOR-POSITIVE AND NEGATIVE HUMAN-BREAST CANCER CELL-LINES [J].
DAVIDSON, NE ;
GELMANN, EP ;
LIPPMAN, ME ;
DICKSON, RB .
MOLECULAR ENDOCRINOLOGY, 1987, 1 (03) :216-223
[7]   Evidence for a role of p38 kinase in hypoxia-inducible factor 1-independent induction of vascular endothelial growth factor expression by sodium arsenite [J].
Duyndam, MCA ;
Hulscher, STM ;
van der Wall, E ;
Pinedo, HM ;
Boven, E .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (09) :6885-6895
[8]  
Feldkamp MM, 1999, INT J CANCER, V81, P118, DOI 10.1002/(SICI)1097-0215(19990331)81:1<118::AID-IJC20>3.0.CO
[9]  
2-5
[10]   VEGF and the quest for tumour angiogenesis factors [J].
Ferrara, N .
NATURE REVIEWS CANCER, 2002, 2 (10) :795-803